219 related articles for article (PubMed ID: 15019272)
1. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).
O'Donnell JM; Zhang HT
Trends Pharmacol Sci; 2004 Mar; 25(3):158-63. PubMed ID: 15019272
[No Abstract] [Full Text] [Related]
2. The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges.
Renau TE
Curr Opin Investig Drugs; 2004 Jan; 5(1):34-9. PubMed ID: 14983971
[TBL] [Abstract][Full Text] [Related]
3. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
[No Abstract] [Full Text] [Related]
4. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.
Zhang HT; Zhao Y; Huang Y; Deng C; Hopper AT; De Vivo M; Rose GM; O'Donnell JM
Psychopharmacology (Berl); 2006 Jun; 186(2):209-17. PubMed ID: 16586089
[TBL] [Abstract][Full Text] [Related]
5. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
Birk S; Edvinsson L; Olesen J; Kruuse C
Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
[TBL] [Abstract][Full Text] [Related]
7. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Doherty AM
Curr Opin Chem Biol; 1999 Aug; 3(4):466-73. PubMed ID: 10419856
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
11. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.
Verhoest PR; Proulx-Lafrance C; Corman M; Chenard L; Helal CJ; Hou X; Kleiman R; Liu S; Marr E; Menniti FS; Schmidt CJ; Vanase-Frawley M; Schmidt AW; Williams RD; Nelson FR; Fonseca KR; Liras S
J Med Chem; 2009 Dec; 52(24):7946-9. PubMed ID: 19919087
[TBL] [Abstract][Full Text] [Related]
12. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats.
Itoh T; Tokumura M; Abe K
Eur J Pharmacol; 2004 Sep; 498(1-3):135-42. PubMed ID: 15363987
[TBL] [Abstract][Full Text] [Related]
13. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
Makhay MM; Houslay MD; O'Donnell JM
Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
[TBL] [Abstract][Full Text] [Related]
14. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
Castro A; Jerez MJ; Gil C; Martinez A
Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
[TBL] [Abstract][Full Text] [Related]
15. Increased building block access through collaboration.
Helal CJ; Bartolozzi A; Goble SD; Mani NS; Guzman-Perez A; Ohri AK; Shi ZC; Subramanyam C
Drug Discov Today; 2018 Aug; 23(8):1458-1462. PubMed ID: 29571837
[No Abstract] [Full Text] [Related]
16. Cyclic AMP phosphodiesterase inhibition by coumarins and furanocoumarins.
Sardari S; Nishibe S; Horita K; Nikaido T; Daneshtalab M
Pharmazie; 1999 Jul; 54(7):554-6. PubMed ID: 10445247
[No Abstract] [Full Text] [Related]
17. Phosphodiesterase-4 as a potential drug target.
Zhang KY; Ibrahim PN; Gillette S; Bollag G
Expert Opin Ther Targets; 2005 Dec; 9(6):1283-305. PubMed ID: 16300476
[TBL] [Abstract][Full Text] [Related]
18. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
[No Abstract] [Full Text] [Related]
19. Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors.
Méhats C; Tanguy G; Paris B; Robert B; Pernin N; Ferré F; Leroy MJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):817-23. PubMed ID: 10640323
[TBL] [Abstract][Full Text] [Related]
20. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
Kass DA
Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
[No Abstract] [Full Text] [Related]
[Next] [New Search]
